{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maio M"],"funding":["GSK"],"pagination":["e011475"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12352173"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(8)"],"pubmed_abstract":["Background
Inducible costimulator (ICOS) receptor belongs to the CD28/CTLA immunoglobulin super family, whose expression is restricted to T cells and is weakly expressed on resting TH17, follicular helper T cells, and regulatory T cells, but is highly induced on CD4+ and CD8+ T cells on activation by T-cell receptors. ICOS stimulation downstream effects include activation of conventional CD4+cells and cytotoxic CD8+cells, resulting in a durable antitumor response in preclinical models.Methods
As part of a larger first-in-human study (GSK Study 204691), this study focused on 2 cohorts of 25 and 67 participants enrolled in a dose escalation and pharmacokinetic/pharmacodynamic (PK/PD) analysis of the ICOS agonist feladilimab (GSK3359609) as monotherapy. For these cohorts, the "],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors."],"pmcid":["PMC12352173"],"funding_grant_id":["NCT02723955","GSK Study 204691","EudraCT 2016-000148-32"],"pubmed_authors":["Hansen A","Bauer TM","Rischin D","Maio M","Ballas M","Opdam F","Italiano A","Ellis C","Turner D","Yadavilli S","Hirschfeld S","Le Tourneau C","Moreno V","Diaz-Padilla I","Martin-Liberal J","Angevin E","Zhou H"],"additional_accession":[]},"is_claimable":false,"name":"First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.","description":"Background
Inducible costimulator (ICOS) receptor belongs to the CD28/CTLA immunoglobulin super family, whose expression is restricted to T cells and is weakly expressed on resting TH17, follicular helper T cells, and regulatory T cells, but is highly induced on CD4+ and CD8+ T cells on activation by T-cell receptors. ICOS stimulation downstream effects include activation of conventional CD4+cells and cytotoxic CD8+cells, resulting in a durable antitumor response in preclinical models.Methods
As part of a larger first-in-human study (GSK Study 204691), this study focused on 2 cohorts of 25 and 67 participants enrolled in a dose escalation and pharmacokinetic/pharmacodynamic (PK/PD) analysis of the ICOS agonist feladilimab (GSK3359609) as monotherapy. For these cohorts, the ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-07-15T10:49:51.362Z","creation":"2026-07-04T03:12:05.598Z"},"accession":"S-EPMC12352173","cross_references":{"pubmed":["40789742"],"doi":["10.1136/jitc-2025-011475"]}}